IP Library › Granted Patent US 11,844,845
Granted Patent B2
US 11,844,845 · App. 16/273,689 · Granted Dec 19, 2023

Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GemVax & KAEL Co., Ltd.
A61K49/0056A23L33/175A23L33/18A61K9/0019A61K47/64A61K49/0043C07K7/08C07K14/00A23V2002/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,844,845
App. No.
16/273,689
Granted
Dec 19, 2023
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (8)

1. A conjugate consisting of a cell penetrating carrier peptide, an active ingredient, and optionally a linker; wherein the carrier peptide is a peptide consisting of any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 9, SEQ ID NO: 11 to SEQ ID NO: 41, and SEQ ID NO: 43 to SEQ ID NO: 77; wherein the conjugate does not comprise the amino acid sequence of telomerase; wherein the carrier peptide and the active ingredient are coupled via a non-covalent bond or a covalent bond; and wherein the active ingredient is a contrast agent.

2. The conjugate according to claim 1 , wherein the contrast agent is selected from the group consisting of radiopaque contrast agent, paramagnetic contrast agent, superparamagnetic contrast agent and computed tomography (CT) contrast agent.

3. The conjugate according to claim 1 , wherein the contrast agent comprises iron.

4. The conjugate according to claim 3 , wherein the contrast agent is a ferrocene carboxylate.

5. The conjugate according to claim 1 , wherein the contrast agent is for contrasting a cell.

6. The conjugate according to claim 5 , wherein the cell is a stem cell.

7. A cell penetrating carrier peptide consisting of any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 42, or SEQ ID NO: 44 to SEQ ID NO: 77.

8. A method of delivering the carrier peptide of claim 7 comprising administering the peptide locally into mitochondria inside a cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 053336/0537 →
Priority Claims (5)
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104173 · Sep 19, 2012 · national
KR 10-2012-0109207 · Sep 28, 2012 · national
KR 10-2012-0109216 · Sep 28, 2012 · national
KR 10-2013-0017046 · Feb 18, 2013 · national
Continuity (3)
Division 15374805 · Dec 9, 2016
Division 14429644
Related Publication 20190269803A1 · Sep 5, 2019